Anthera gets $36M in VC
|
VENTURE CAPITAL |
|||
|
COMPANY |
AMOUNT/ROUND |
LEAD INVESTORS |
DESCRIPTION |
|
Anthera Pharmaceuticals
|
$36M
|
Venture Partners and Sofinnova Ventures |
The funding will be used for the clinical development of its newly-licensed anti-inflammatory compounds. |
|
Addex Pharmaceuticals
|
$32M
|
SR One |
The funding will be used to develop Addex's clinical and pre-clinical drug candidates. |
|
Alvine Pharmaceuticals
|
$21M
|
Sofinnova Ventures |
Alvine is developing a treatment for celiac sprue. |
|
ActoGenix
|
$15M
|
GIMV and Life Sciences Partners |
The financing will allow ActoGeniX to initiate development of a pipeline of therapeutic products based on its TopAct technology platform. |
|
NuPathe
|
$15M
|
Birchmere Ventures |
The financing will support NuPathe's clinical programs related to therapeutic products to treat migraine and other CNS disorders. |
|
Pepscan Systems
|
$9M
|
BioX Biosciences |
The funds will be used to continue and expand development of its existing portfolio of therapeutic vaccines programs. |